Jeffrey Cohen

Ozanimod: long-term safety and efficacy in relapsing MS 1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen • 24 Feb 2022
ACTRIMS research priorities 1:35
ACTRIMS research priorities
Jeffrey Cohen • 24 Feb 2022
Unmet needs in multiple sclerosis 1:01
Unmet needs in multiple sclerosis
Jeffrey Cohen • 24 Feb 2022
How to approach MS treatment sequencing in a crowded therapeutic market 1:13
How to approach MS treatment sequencing in a crowded therapeutic market
Jeffrey Cohen • 24 Feb 2022
Developing novel biomarkers in MS: diagnostic, predictive, & prognostic 1:15
Developing novel biomarkers in MS: diagnostic, predictive, & prognostic
Jeffrey Cohen • 24 Feb 2022
ACTRIMS day 1 highlights with Jeffrey Cohen 1:39
ACTRIMS day 1 highlights with Jeffrey Cohen
Jeffrey Cohen • 24 Feb 2022
The content of VJNeurology is intended for healthcare professionals